- Zacks•5 days ago
Keryx Biopharmaceuticals, Inc. (KERX) recently announced the publication of results from a phase III in the online issue of the Journal of the American Society of Nephrology (JASN).
- GlobeNewswire•6 days agoKeryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology
BOSTON, Jan. 12, 2017-- Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced the publication of results from ...
- GlobeNewswire•10 days agoKeryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference
Enters 2017 with positive momentum for Auryxia ® in dialysis; preliminary unaudited fourth quarter net U.S. product sales of $8.2 million Submitted supplemental new drug application seeking Auryxia label ...
KERX : Summary for Keryx Biopharmaceuticals, Inc. - Yahoo Finance
Keryx Biopharmaceuticals, Inc. (KERX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||5.93 x 1000|
|Ask||6.15 x 600|
|Day's Range||5.95 - 6.11|
|52 Week Range||2.80 - 7.80|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|